pharmaphorum August 29, 2024
Novartis is putting $20 million upfront into a near-$1 billion deal with US start-up Lindy Biosciences that aims to convert biologic drugs delivered by infusion into therapies that can be self-injected by the patient.
The worldwide licensing deal signals a major leap forward for Morrisville, North Carolina-based Lindy, which was formed in 2016 to develop its proprietary ‘microglassification’ suspension technology, and should accelerate the start of human trials of drugs using the system.
Microglassification involves removing the water from solutions of proteins, antibodies or other biologic drugs in a way that forms solid, spherical, amorphous microbeads. Those microbeads are dry, stable, and highly concentrated – and crucially they can be formulated into the small volumes needed for subcutaneous injections.
Currently,...
Today's Sponsors
Today's Sponsor